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forBACKGROUND Blood transfusion is controversial for anemic patients with acute myocardial infarction (AMI), with
some previous studies reporting increased risk of transfusion-associated mortality.
OBJECTIVES The goal of this study was to examine variability in blood transfusions across hospitals and the
relationship between blood transfusion and in-hospital mortality in a large, contemporary cohort of consecutive
AMI patients.
METHODS Among 34,937 AMI hospitalizations from 57 centers, patients receiving at least 1 packed red blood cell
transfusion were compared with those who were not transfused. Using 45 disease severity, comorbidity, laboratory,
and in-hospital treatment variables, we propensity matched patients who did and did not receive a packed red blood
cell transfusion. A conditional logistic regression model was used to identify the association between transfusion and
in-hospital mortality.
RESULTS A total of 1,778 patients (5.1%) had at least 1 transfusion. In unadjusted analyses, transfusion was associated
with higher in-hospital mortality (odds ratio: 2.05 [95% conﬁdence interval: 1.76 to 2.40]). The vast majority of patients
(91.1%) with and without transfusion had nonoverlapping propensity scores, reﬂecting incomparable clinical proﬁles.
Thus, they were excluded from the propensity-matched analyses. After propensity matching those with overlapping
scores, blood transfusion was associated with a reduced risk of in-hospital death (odds ratio: 0.73 [95% conﬁdence
interval: 0.58 to 0.92]).
CONCLUSIONS The majority of patients undergoing blood transfusion in clinical practice cannot be matched with
nontransfused patients due to their markedly different clinical proﬁles. Among comparable patients, blood transfusion
was associated with a lower risk of in-hospital mortality. These ﬁndings suggest that previous observational reports
of increased mortality with transfusion may have been inﬂuenced by selection bias, and they highlight the need for
randomized trials to establish the role of transfusion during AMI. (J Am Coll Cardiol 2014;64:811–9) © 2014 by the
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812A nemia is common at the time ofacute myocardial infarction (AMI)and has been shown to portend
a poor prognosis, including greater short-
term and long-term mortality (1–4). In the
setting of AMI, administration of packed
red blood cells may augment hemoglobin
levels and improve myocardial oxygen de-
livery, but it also carries risks, including vol-
ume overload, increased thrombogenicity,
impaired oxygen delivery, and a risk of in-
fection (5,6). Despite the widespread useof blood transfusions in clinical practice, the safety
and efﬁcacy of this method have not been evaluated
in large, randomized clinical trials. Accordingly, the
use of blood transfusion in AMI patients remains
controversial, with some observational studies sug-
gesting beneﬁt in patients with low nadir hemo-
globin values (1,7,8), whereas others have reported
increased mortality (9–11).SEE PAGE 820A major challenge in the interpretation of trans-
fusion and outcomes in observational studies is the
impact of confounding. Clinicians select treatments,
such as transfusion, after considering a broad array
of factors, including the perceived beneﬁts and
risks for each individual patient. In such cases, ob-
servational studies may yield a relationship between
treatment and outcome that primarily reﬂects the
underlying high-risk characteristics of treated pa-
tients. Although confounding can be minimized by
the use of instrumental variables or propensity
matching (12), these methods have not been uni-
formly used in previous research.
To further illuminate the association between
transfusion and survival in anemic AMI patients,
we used the Cerner Health Facts database (13,14),
which collects data through the electronic medical
record on consecutive AMI patients at 57 U.S. hospi-
tals. Given the large size of the patient population
and the detailed collection of in-hospital laboratory,
treatment, and complication data, we were able to
conduct a propensity-matched analysis to speciﬁcally
focus on the patients eligible for transfusion.(11GRNT7330005), Gilead Sciences (IN-US-259-0159) (with Dr. S
etrics, Maquet, and Eisai; and has served as a consultant or on
La Roche, Medtronic Diabetes, AstraZeneca, AbbVie, Regeneron,
rs have reported that they have no relationships relevant to the
is manuscript’s audio summary by JACC Editor-in-Chief Dr. Vale
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received January 6, 2014; revised manuscript received April 10,Importantly, some patients have such life-threatening
anemia that they would always be transfused, while
other, “healthier” patients would rarely receive a
transfusion; inclusion of such patients could lead to
substantial selection bias. Finally, given the diverse
collection of hospitals participating inHealth Facts, we
were able to examine the variability in blood trans-
fusion practices across institutions in real-world
practice.
METHODS
Health Facts captured de-identiﬁed data from
the Cerner electronic medical record for patients
admitted to participating hospitals between January 1,
2000, and December 31, 2008. Data collected in-
cluded patients’ demographic characteristics, medical
history, and comorbidities (using the International
Classiﬁcation of Diseases-Ninth Revision-Clinical
Modiﬁcation [ICD-9-CM], codes), laboratory studies,
medications, procedures, and complications. A total of
78 hospitals contributed data to Health Facts. The
median number of AMI patients from each hospital
was 219 (interquartile range [IQR]: 48 to 1,030), and
the median duration of hospitals’ participation was
2.9 years (IQR: 1.2 to 5.3 years). All data were de-
identiﬁed before being provided to the investigators,
and the institutional review board of Saint Luke’s
Hospital provided an exemption to review.
We included all patients hospitalized with a pri-
mary discharge diagnosis of AMI as determined by
using ICD-9-CM diagnostic codes 410.xx, and AMI
was further conﬁrmed by requiring that patients
have at least 1 elevated cardiac biomarker (troponin
or creatine kinase-myocardial band). Patients known
to be transferred from other hospitals (full laboratory
testing data may not be available) or from hospice
(goals of care differ from the overall population)
were excluded. Inclusion and exclusion criteria are
listed in detail in Figure 1. Important exclusions were
patients admitted from hospitals contributing <20
patients to Health Facts, those with very long lengths
of stay (>31 days), and patients who underwent
coronary bypass grafting, valve replacement, or valve
repair during hospitalization. Patients without apertus), Genentech, Sanoﬁ-Aventis, Medtronic Dia-
the advisory board of Gilead Sciences, Genentech,
Edwards Lifesciences, ZS Pharma, and Eli Lilly. All
contents of this paper to disclose.
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AMI diagnosis + elevated 
cardiac biomarkers
N=40,699
n=40,229
n=36,099
N = 34,937  
from 57 hospitals
Hospital enrolling < 20pts 
(n=59), LOS > 31 days (n=411) 
CABG during admission 
(n=4,089), Valve surgery 
during admission (n=41)
No Hgb recorded  (n=588),  
Length of stay < 1 day (n=574)
FIGURE 1 Patient Population
Inclusions and exclusions. AMI ¼ acute myocardial infarction;
CABG ¼ coronary artery bypass grafting; Hgb ¼ hemoglobin;
LOS ¼ length of stay.
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813recorded hemoglobin assessment and any patient
with a length of stay <1 day were also excluded. The
ﬁnal analytic cohort included 34,937 patients with
AMI from 57 hospitals.
Blood transfusion was deﬁned by using ICD-9
procedure codes for administration of packed red
blood cells, and each patient with an ICD-9 code for
packed cell administration recorded during their in-
dex hospitalization was considered to have received
a red blood cell transfusion. In-hospital mortality
was the primary outcome.
Baseline patient characteristics, laboratory values,
in-hospital treatments, and complications of patients
who received at least 1 packed red blood cell trans-
fusion were compared with those who did not. For
descriptive purposes, categorical data are presented
as frequencies, and groups were compared by using
chi-square tests. Continuous variables are reported
as mean  SD, and differences were compared by
using Student t tests. We used the Wilcoxon rank
sum test to compare variables with skewed distribu-
tions, and results are reported as median and IQR.
To assess the association between transfusion
status and in-hospital mortality, we ﬁrst used a
non-parsimonious propensity model to calculate
the likelihood of transfusion based on all available
patient characteristics for each patient, including 45
variables (Table 1). Importantly, these variables in-
cluded multiple in-hospital hemoglobin assessments,
key treatments, and complications during hospitali-
zation, including acute renal failure, in-hospitalshock, septic shock, cardiogenic shock, and in-
hospital mechanical ventilation. After calculating
propensity scores for the likelihood of transfusion for
each patient, propensity scores of patients with and
without transfusion during AMI hospitalization were
examined for overlap. Comparable patients in the
overlapping region of the propensity to be transfused
were then stratiﬁed according to transfusion status,
and those who were transfused were matched in a
1-to-many fashion with those not transfused (because
a larger proportion of AMI patients in this cohort did
not receive a transfusion), using a caliper width of
0.5. This caliper width is 0.5 times the SD of the logit
of the propensity score for transfusion and reﬂects
the maximum difference in propensity score between
treated and untreated patients that would still allow
matching. The adequacy of propensity matching was
then assessed by calculating post-match standardized
differences and examining patient characteristics
post-matching. A signiﬁcant imbalance was consid-
ered to be present if a >10% standardized difference
was present between the 2 groups after propensity
matching (15).
Another clinically important question is whether
the relationship between transfusion and mortality
differs depending on nadir hemoglobin. Because
propensity matching incorporates the use of nadir
hemoglobin, it eliminates the ability to study this
interaction and also limits sample size, precluding
stratiﬁcation on nadir hemoglobin. Accordingly, we
conducted separate analyses in the total patient
population (N ¼ 34,937) to assess the interaction
between nadir hemoglobin level and transfusion.
Patients were stratiﬁed according to nadir hemo-
globin level (<7 g/dl, 7 to 8.9 g/dl, 9 to 10.9 g/dl,
and $11 g/dl), and we compared the in-hospital
mortality of patients with and without transfusion
within strata of nadir hemoglobin. This analysis was
then repeated by using hierarchical multivariable
logistic regression to account for clustering within
hospital site and adjusted for confounding related
to patients’ clinical characteristics.
To examine variability in transfusion practices
across hospitals while generating conservative esti-
mates of variation, we excluded patients from any
hospital reporting no blood transfusions and hospitals
in which the absolute observed transfusion rate varied
from the expected transfusion rate by >10%. When
comparing transfusion rates across hospitals, shrink-
age estimates were generated by using a hierarchical
model including site as a random effect (with no
additional covariates) to account for lower enrollment
from small hospitals. This approach pulls estimates
from smaller hospitals toward the overall mean
TABLE 1 Characteristics of Patients With and Without Blood Transfusion During Acute Myocardial Infarction Hospitalization
Pre-Match Post-Match
Transfusion
(n ¼ 1,778)
No Transfusion
(n ¼ 33,159) p Value
Transfusion
(n ¼ 1,121)
No Transfusion
(n ¼ 1,987) p Value*
Age, yrs 76.7  10.8 68.3  14.6 <0.001 76.2  11.0 76.3  11.8 0.6789
White 1,543 (87.0%) 28,669 (86.9%) 0.864 963 (86.2%) 1,716 (86.5%) 0.6893
Female 982 (55.2%) 13,752 (41.5%) <0.001 635 (56.6%) 1,134 (57.1%) 0.9797
ST-segment elevation MI 304 (17.1%) 12,219 (36.8%) <0.001 235 (21.0%) 418 (21.0%) 0.5290
Diabetes 751 (42.2%) 10,148 (30.6%) <0.001 460 (41.0%) 858 (43.2%) 0.3388
Hypertension 899 (50.6%) 18,484 (55.7%) <0.001 586 (552.3%) 1,039 (52.3%) 0.7523
Heart failure 1,093 (61.5%) 10,339 (31.2%) <0.001 662 (59.1%) 1,205 (60.6%) 0.2705
Dyslipidemia 269 (15.1%) 13,698 (41.3%) <0.001 269 (16.6%) 336 (16.9%) 0.6808
History of stroke/TIA 67 (3.8%) 997 (3.0%) 0.069 45 (4.0%) 78 (3.9%) 0.8189
History of peripheral arterial disease 50 (2.8%) 825 (2.5%) 0.394 29 (2.6%) 51 (2.6%) 0.9682
Chronic kidney disease 576 (32.4%) 3,585 (10.8%) <0.001 328 (29.3%) 619 (31.2%) 0.2585
End-stage renal disease 190 (10.7%) 971 (2.9%) <0.001 109 (9.7%) 196 (9.9%) 0.7696
Baseline GFR, ml/min/1.73 m2, MDRD 39.5 (25.4–56.8) 64.0 (45.3–82.2) <0.001 41.5 (26.7–58.9) 38.9 (25.5–56.7) 0.1405
Chronic lung disease 374 (21.0%) 4,508 (13.6%) <0.001 238 (21.2%) 398 (20.0%) 0.6356
Dementia 34 (1.9%) 708 (2.1%) 0.525 23 (2.1%) 33 (1.7%) 0.3645
Chronic liver disease 20 (1.1%) 135 (0.4%) <0.001 13 (1.2%) 18 (0.9%) 0.5304
Previous MI 72 (4.0%) 2,243 (6.8%) <0.001 48 (4.3%) 86 (4.3%) 0.9005
History of PCI 42 (2.4%) 2,139 (6.5%) <0.001 32 (2.9%) 51 (2.6%) 0.4768
History of CABG 83 (4.7%) 1,708 (5.2%) 0.369 53 (4.7%) 103 (5.2%) 0.6667
Active smoking 82 (4.6%) 7,753 (23.4%) <0.001 62 (5.5%) 106 (5.3%) 0.7121
Admission hemoglobin, g/dl 9.7 (8.6–11.1) 13.5 (12.0–14.7) <0.001 10.1 (9.0–11.5) 10.8 (9.8–12.1) <0.0001
Nadir hemoglobin, g/dl 8.3 (7.6–8.8) 12.0 (10.4–13.3) <0.001 8.5 (8.0–9.0) 8.9 (8.2–9.5) <0.0001
Discharge hemoglobin, g/dl 10.5 (9.8–11.3) 12.3 (10.9–13.7) <0.001 10.6 (9.80–11.4) 9.90 (9.20–10.70) <0.0001
Length of stay, days 8.8  5.5 5.2  4.0 <0.001 8.5  5.4 8.5  5.8 0.9584
In-hospital bleeding 455 (25.6%) 1755 (5.3%) <0.001 230 (20.5%) 326 (16.4%) 0.1589
Acute respiratory failure 203 (11.4%) 2151 (6.5%) <0.001 141 (12.6%) 235 (11.8%) 0.4765
In-hospital mechanical ventilation 148 (8.3%) 1494 (4.5%) <0.001 110 (9.8%) 185 (9.3%) 0.5728
Acute renal failure 429 (24.1%) 2,703 (8.2%) <0.001 239 (21.3%) 470 (23.7%) 0.1021
Cardiogenic shock 69 (3.9%) 1,138 (3.4%) 0.313 57 (5.1%) 92 (4.6%) 0.5341
Septic shock 32 (1.8%) 126 (0.4%) <0.001 18 (1.6%) 27 (1.4%) 0.6775
In-hospital dialysis 149 (8.4%) 707 (2.1%) <0.001 89 (7.9%) 153 (7.7%) 0.9251
Intravenous heparin 1,058 (59.5%) 23,331 (70.4%) <0.001 1,058 (59.5%) 1,325 (66.7%) 0.3205
ACE inhibitor or ARB 951 (53.5%) 21,111 (63.7%) <0.001 639 (57.0%) 1,117 (56.2%) 0.5429
Aspirin 1,322 (74.4%) 28,509 (86.0%) <0.001 879 (78.4%) 1,550 (78.0%) 0.5035
Beta-blocker 1,485 (83.5%) 27,860 (84.0%) 0.576 936 (83.5%) 1,664 (83.7%) 0.8794
Statin 999 (56.2%) 21,806 (65.8%) <0.001 598 (53.3%) 1,095 (55.1%) 0.5327
Diuretics 1,315 (74.0%) 13,960 (42.1%) <0.001 811 (72.3%) 1,434 (72.2%) 0.6042
Glycoprotein IIb/IIIa antagonist 303 (17.0%) 13,767 (41.5%) <0.001 229 (20.4%) 384 (19.3%) 0.2980
Thienopyridine 718 (40.4%) 21,839 (65.9%) <0.001 493 (44.0%) 856 (43.1%) 0.2422
Long-acting insulin 320 (18.0%) 3,083 (9.3%) <0.001 189 (16.9%) 358 (18.0%) 0.4997
Short-acting insulin 557 (31.3%) 5,921 (17.9%) <0.001 354 (31.6%) 624 (31.4%) 0.9892
Fibrinolytics 44 (2.5%) 1,025 (3.1%) 0.141 29 (2.6%) 55 (2.8%) 0.7587
Warfarin 211 (11.9%) 3,563 (10.7%) 0.138 134 (12.0%) 237 (11.9%) 0.9385
Oral hypoglycemic 325 (18.3%) 4,670 (14.1%) <0.001 177 (15.8%) 352 (17.7%) 0.1863
Calcium channel blocker 537 (30.2%) 7,211 (21.7%) <0.001 332 (29.6%) 588 (29.6%) 0.9011
In-hospital coronary angiography 415 (23.3%) 21,125 (63.7%) <0.001 349 (31.1%) 573 (28.8%) 0.0536
In-hospital percutaneous coronary intervention 144 (8.1%) 15,500 (46.7%) <0.001 139 (8.1%) 220 (11.1%) 0.0621
Values are mean  SD, n (%), or median (interquartile range). Continuous variables were compared by using the Student t test. Categorical variables were compared by using chi-square or the
Fisher exact test. *p values in the post-match patients were controlled for matched strata. In these analyses, continuous variables compared by using linear regression controlled for match
strata and categorical variables were compared by using Cochran-Mantel-Haenszel test.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; CABG ¼ coronary artery bypass grafting; GFR ¼ glomerular ﬁltration rate; MDRD ¼Modiﬁcation of Diet in Renal
Disease; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention; TIA ¼ transient ischemic attack.
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815because the crude transfusion rates at sites with small
enrollments are unduly inﬂuenced by only a few
transfusion events. Estimates were generated by us-
ing a generalized linear model, regressing site as a
random effect on transfusion rate as the dependent
variable. To adjust for case-mix differences, median
odds ratios (ORs) were then calculated to assess the
variability in transfusion rates independent of patient
characteristics (16). The median OR reﬂects the me-
dian value of the ORs for the risk of transfusion if
2 patients with identical characteristics presented to
all possible pairs of Health Facts hospitals. Statistical
analyses were conducted by using SAS version 9.2
(SAS Institute, Inc., Cary, North Carolina).
RESULTS
At least 1 packed red blood cell transfusion was
administered to 1,778 patients (5.1%). Patients who
were transfused differed markedly from those who
were not with respect to a host of prognostically
important variables (Table 1). They were older,
had much lower hemoglobin values throughout
their hospital course, a greater burden of in-hospital
complications, and a signiﬁcantly longer length of
hospitalization compared with nontransfused pa-
tients. Transfused patients were much less likely
to undergo angiography or percutaneous coronary
intervention and to receive medical therapies suchCENTRAL ILLUSTRATION Patients’ Propensity Scores for Blood T
and In-Hospital Mortality
(Left) Plot of propensity scores to receive blood transfusion at the time
patient’s likelihood of transfusion as predicted by the propensity model
transfusion. (Right) Pre- and post-match association between transfusioas aspirin, thienopyridines, angiotensin-converting
enzyme inhibitors, or angiotensin receptor blockers.
Patients who received a blood transfusion had
signiﬁcantly higher mortality than those who did
not (11.0% vs. 5.7%; unadjusted OR: 2.05 [95% conﬁ-
dence interval (CI): 1.76 to 2.40]; p < 0.001). How-
ever, there was substantial baseline imbalance in
key clinical characteristics, as evidenced by a plot
of propensity scores (Central Illustration). In fact,
31,829 (91.1%) patients had nonoverlapping propen-
sity scores for blood transfusion and could not be
matched based on propensity for transfusion.
After propensity matching the remaining pop-
ulation (n ¼ 3,108 [n ¼ 1,121 transfused and n ¼ 1,987
not transfused]), there were no longer signiﬁ-
cant imbalances in clinical characteristics, with all
post-matching standardized differences being <10%
(Fig. 2). In contrast to the unadjusted analyses, after
adequate propensity matching, blood transfusion
was associated with a lower in-hospital mortality
(OR: 0.73 [95% CI: 0.58 to 0.92]).
In additional analyses, a marked variation was
noted in the association between transfusion and
mortality stratiﬁed according to nadir hemoglobin
(Fig. 3). In unadjusted analyses, transfusion was
associated with lower risk of mortality among those
with nadir hemoglobin values <7 g/dl (OR: 0.52
[95% CI: 0.32 to 0.84]) and between 7 and 8.99 g/dl
(OR: 0.73 [95% CI: 0.6 to 0.9]). There was noransfusion and Association Between Transfusion
of acute myocardial infarction according to transfusion status. Each
is plotted, comparing patients who did and did not receive a blood
n and in-hospital mortality. CI ¼ conﬁdence interval; OR ¼ odds ratio.
Minimum Hgb
In-hospital PCI
In-hospital CATH
Diuretics
Age
Heart failure
GI bleed
Dyslipidemia
Other heart failure
Bleeding event
Smoking status
GP IIa/IIIb
History of CAD
CKD
Platelet inhibitors
ST-elevation MI
Acute renal disease
Non ST-elevation MI 
Bronchodilators
Insulin
Short-acting insulin
End stage renal disease
Aspirin
Dialysis procedure
Female
Long-acting insulin
Diabetes
Heparin
ACE inhibitors
ACE/ARB
History of PCI
Lung disease
Statin
Calcium-channel blockers
Systolic heart failure 
Acute respiratory failure
In-hospital mechanical ventilation
Diastolic heart failure
Septic shock
50 100 150 200
Standardized Difference (%)
Prior MI
Any shock
Oral glucose medications
Diabetes: Type 1
Miscellaneous bleed
Hypertension
Other shock
Before matching
After matching
FIGURE 2 Pre- and Post-Matching Standardized Differences
Only variables that were poorly balanced (standardized difference $10%) before
propensity matching are presented in the graphic. The dashed vertical line represents
a 10% standardized difference between patients with and without transfusion. ACE ¼
angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; CAD ¼ coronary
artery disease; CATH ¼ coronary angiography; CKD ¼ chronic kidney disease; GI ¼
gastrointestinal; GP ¼ glycoprotein; MI ¼ myocardial infarction; PCI ¼ percutaneous
coronary intervention; other abbreviation as in Figure 1.
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816signiﬁcant relationship of transfusion with mortality
among those with nadir hemoglobin values between
9 and 10.99 g/dl, whereas transfusion was associ-
ated with higher mortality among those with nadir
hemoglobin values $11 g/dl (OR: 6.28 [95% CI: 2.12 to
18.6]). After adjustment for site and patient charac-
teristics, the trend of lower mortality among trans-
fused patients below a nadir hemoglobin of 9 g/dl
persisted, but the apparent hazard of transfusion
for patients with nadir hemoglobin $11 g/dl was
attenuated (OR: 1.88 [95% CI: 0.40 to 8.78]).
There was substantial variability in the rate of
transfusion across hospitals (Fig. 4). After applying
additional exclusions as described in the Methods,
1,175 (7.4%) of the remaining 24,083 patients received
at least 1 red blood cell transfusion. Shrinkage-
adjusted transfusion rates ranged from 3.1% to 14.5%.
The median OR for transfusion was 2.0 (95% CI: 1.5 to
2.5), indicating a 2-fold variability in blood transfusionrates across hospitals for 2 randomly selected patients
with identical clinical characteristics.
DISCUSSION
In this large, multicenter study of AMI patients
reﬂecting real-world clinical practice, we found
that patients who received blood transfusions had
higher in-hospital mortality than those who were
not transfused but that this ﬁnding largely reﬂects
their higher risk clinical characteristics. After pro-
pensity matching, the relationship between trans-
fusion and higher mortality was eliminated (Central
Illustration). We also identiﬁed marked variability in
case-mix–adjusted transfusion rates across hospitals,
likely indicating substantial variation in hospital-
and provider-speciﬁc blood transfusion practices.
The only randomized trial to assess the impact
of transfusion on outcomes at the time of AMI was
CRIT (Conservative versus Liberal Red Cell Trans-
fusion in Acute Myocardial Infarction), a small pilot
study that found an excess in the composite outcome
of death, recurrent myocardial infarction (MI), or
heart failure when patients were transfused below a
hematocrit level of 30% compared with a more con-
servative threshold of 24% (17). This ﬁnding was
driven entirely by the development of heart failure,
and the authors observed no difference in the com-
bined endpoint of mortality or recurrent AMI. A host
of observational studies have been conducted and
have reached varying conclusions. Wu et al. (7) found
that transfusion was associated with lower 30-day
mortality among elderly patients with MI below a
hematocrit threshold of 33%. In contrast, several
studies reported increased mortality among patients
treated with blood transfusion (9–11). A recent meta-
analysis by Chatterjee et al. (10) reported that blood
transfusion was associated with a nearly 3-fold in-
crease in mortality. However, many studies included
in this meta-analysis had limitations related to the
assessment of patient-level characteristics (presence
and severity of comorbidities, inclusion of multiple
hemoglobin assessments), as well as in the robustness
of statistical methods used.
Several previous studies have used propensity score
adjustment, which is a less robust tool to minimize
confounding compared with propensity matching (12).
Our ﬁnding that the vast majority of patients in Health
Facts had nonoverlapping propensity scores strongly
suggests that the use of multivariable regression with
or without propensity score adjustment may not be
adequate to address the considerable selection bias
inherent in comparing the outcomes of transfused
and nontransfused patients. Both the large size and
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FIGURE 3 Transfusion and Mortality Stratiﬁed According to Nadir Hgb
Association of transfusion with mortality stratiﬁed according to lowest in-hospital Hgb
value. A total of 227 (42.3%) of 537 patients with nadir Hgb <7 g/dl, 1,210 (29.5%) of
4,098 with nadir 7 to 8.9 g/dl, 319 (3.9%) of 8,083 with nadir 9 to 10.9 g/dl, and 22
(0.1%) of 22,219 with nadir $11 g/dl were transfused. CI ¼ conﬁdence interval; OR ¼ odds
ratio; other abbreviation as in Figure 1.
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FIGURE 4 Variation in Blood Transfusion Rates Across Health Facts Hospitals
Shrinkage-adjusted rates of blood transfusion at the time of acute myocardial infarction
across participating hospitals in Health Facts, ranked from lowest to highest transfusion
incidence.
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817detailed patient-level data available in the present
study allowed exclusion of patients with nonover-
lapping propensity scores, while still preserving the
sample size necessary to ﬁnd a clinically important
difference in mortality; this was likely not possible in
smaller previous studies. One previous study did
match patients on propensity to be transfused; in
contrast to our study, the authors found that trans-
fusion was associated with increased mortality (11).
However, they did not include nadir hemoglobin in
propensity matching, choosing instead to adjust for
nadir hemoglobin after the match was completed. In
our study, there was a >200% standardized differ-
ence in nadir hemoglobin between those who were
and were not transfused; given the strong prognostic
implications of severe in-hospital anemia, not
including nadir hemoglobin in propensity matching
may erroneously attribute the adverse prognostic
impact of anemia to blood transfusion. Moreover, the
propensity model in this study did not include key
in-hospital complications, such as acute renal failure,
mechanical ventilation, shock, and requirement for
hemodialysis. These variables differed greatly be-
tween transfused and nontransfused patients in our
study (each with a standardized difference >10%
before matching), and given the strong prognostic
value of these factors, their exclusion could produce a
strong confounding effect.
Previous randomized studies examining other
patient populations found similar outcomes be-
tween conservative and liberal transfusion strategies.
Examining critically ill patients randomized to a
transfusion threshold of 7 g/dl versus 10 g/dl, Hebert
et al. (18) found no signiﬁcant difference in 30-day
mortality. Similarly, there was no difference in the
composite of 30-day mortality or morbidity com-
paring a liberal versus a conservative transfusion
strategy among cardiac surgery patients in the TRACS
(Transfusion Requirement After Cardiac Surgery) trial
(19). Similar results were observed in a trial of pa-
tients with coronary disease or coronary disease risk
factors undergoing hip surgery (20). A recent meta-
analysis summarizing trials of transfusion to date
across a variety of populations found a modestly
lower in-hospital mortality among patients managed
with a restrictive versus more liberal transfusion
goal (relative risk: 0.77 [95% CI: 0.62 to 0.95]) but no
difference in 30-day mortality (relative risk: 0.85
[95% CI: 0.70 to 1.03]) (21,22). In contrast, a recent
trial including patients with upper gastrointestinal
bleeding found lower mortality rates among pa-
tients assigned to a restrictive transfusion strategy
(23). Whether these ﬁndings generalize to patients
presenting with MI is unclear, and practiceguidelines acknowledge this lack of certainty with
regard to transfusion practices in AMI (24). Regard-
less, these data, coupled with our ﬁndings, argue
against a 2-fold increase in mortality attributable to
blood transfusion in AMI as suggested by previous
observational literature.
The optimal threshold for blood transfusion during
AMI remains a subject of debate. We observed a
trend toward improved outcomes associated with
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Severe anemia is common in patients hospitalized
with AMI, but blood transfusion is controversial, given
the lack of evidence of a favorable impact on patient
outcomes.
COMPETENCY IN PATIENT CARE 1: In a large
cohort of consecutive propensity-matched patients
with AMI, blood transfusions were not associated with
a greater risk of adverse outcomes.
COMPETENCY IN PATIENT CARE 2: In the
absence of deﬁnitive data from randomized trials,
clinicians should determine whether to transfuse
blood to individual patients with AMI based on careful
consideration of beneﬁts and risks.
TRANSLATIONAL OUTLOOK: Randomized trials
are necessary to overcome selection bias and to
further investigate the relationship between blood
transfusion and clinical outcomes in patients with
AMI.
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818transfusion below a hemoglobin threshold of 9 g/dl,
which was not seen at higher nadir hemoglobin
values. This ﬁnding is consistent with previous anal-
yses that have suggested a possible beneﬁt from
transfusion for patients with lower nadir hemoglobin
(1,7,8). Our results are also consistent with data from
a small pilot study of liberal (transfusion threshold
of 10 mg/dl) versus conservative transfusion in
patients with symptomatic coronary artery disease
(25). The authors found a lower rate of death and
a trend toward a reduced composite of death, MI,
or unscheduled revascularization among patients
randomized to the liberal transfusion strategy.
Until additional data from randomized trials are
available to guide clinical practice, it seems rea-
sonable to consider transfusion during AMI below
“conservative thresholds.” However, these data un-
derscore signiﬁcant uncertainty in the beneﬁts and
risks of transfusion, necessitating clinicians’ careful
consideration of individual patient factors, which
may inﬂuence the decision to provide a blood trans-
fusion. We also observed dramatic variation in the
frequency of blood transfusion across hospitals.
Importantly, a 2-fold variability remained even after
extensive adjustment for patient characteristics,
indicating that hospital and provider factors likely
drive substantial variability in provision of blood
transfusion. This variability likely reﬂects clinical
uncertainty regarding beneﬁts and risks of transfu-
sion during AMI and represents an important target
for future research. Given the absence of adequately
powered trials to describe the relationship between
transfusion and outcomes in patients with AMI, our
ﬁndings also suggest that it is premature to consider
using transfusion rates as a quality metric.
STUDY LIMITATIONS. Our results should be inter-
preted in the context of the following limitations.
First, the number of units of blood administered
with each transfusion event was not recorded. The
number of units transfused has been shown to
correlate with outcomes (19), likely reﬂecting that
lower nadir hemoglobin portends a poorer prognosis.
Our deﬁnition of AMI was based on the combination
ICD-9 codes and elevated cardiac biomarkers, and
it could have included some patients with a type
II non–ST-segment elevation MI. However, type II
MI has been shown to be prognostically important
(26), and the potential beneﬁt of improved oxygen
delivery may be even more important in patients
whose AMI is driven primarily by demand ischemia.
Finally, although propensity matching is one of the
most robust methods to address observed confound-
ing in nonrandomized comparisons, the possibility
of residual and unmeasured confounding cannotbe excluded. Selection bias cannot be completely
eliminated from observational studies examining in-
terventions, such as blood transfusion, for which
physicians have strong treatment preferences. More-
over, use of this method, which required exclusion
of the majority of patients in Health Facts from
the primary analysis, could limit generalizability of
our ﬁndings.
CONCLUSIONS
We found that the majority of patients who received
a blood transfusion during AMI hospitalization
were not comparable to those who were not trans-
fused, due to marked differences in multiple prog-
nostically important characteristics. Although blood
transfusion was initially associated with increased
mortality, this association was eliminated by pro-
pensity matching, suggesting that this apparent rela-
tionship between transfusion and mortality is largely
driven by selection bias. Randomized trials are
needed to determine appropriate blood transfusion
thresholds in patients with AMI.
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